Johns Hopkins Univ Company Profile

What is the competitive landscape for JOHNS HOPKINS UNIV

JOHNS HOPKINS UNIV has one approved drug.

Summary for Johns Hopkins Univ

US Patents:	0
Tradenames:	1
Ingredients:	1
NDAs:	1
Drug Master File Entries:	1

Drugs and US Patents for Johns Hopkins Univ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Johns Hopkins Univ	AMMONIA N 13	ammonia n-13	INJECTABLE;INTRAVENOUS	204514-001	Aug 19, 2014	AP	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Johns Hopkins Univ
• Johnson And Johnson
• Johnson Johnson Visn

Johns Hopkins University – Market Position, Strengths & Strategic Insights in the Pharmaceutical Landscape

Last updated: February 28, 2026

What is Johns Hopkins University’s Role in the Pharmaceutical and Biotech Sector?

Johns Hopkins University (JHU) is a leading academic research institution focusing on biomedical sciences, drug discovery, and translational research. It operates through its School of Medicine, the Bloomberg School of Public Health, and affiliated research centers. The university’s involvement in pharmaceutical innovation encompasses drug discovery, clinical trials, and licensing technology for commercialization, but it does not directly manufacture drugs.

How Does JHU’s Market Position Compare to Industry and Academic Peers?

Metric	Johns Hopkins University	Leading Academic Peers	Industry Leaders
Research Funding (2022)	$2.05 billion	Harvard: $1.23 billion	Pfizer, Moderna, Novartis (public companies)
Number of Patents Filed (2022)	Over 1,300	Harvard: 800+	Thousands annually (large pharmaceutical firms)
External Licensing Income (2021-22)	Estimated $20-30 million	Not publicly disclosed	Billions for industry giants
NIH Funding (2022)	Over $400 million	Stanford and Harvard over $400 million	Industry’s R&D spend exceeds $1 trillion annually
Spin-off & Startup Formation	Over 30 companies launched since 2010	MIT: 30+; Stanford: 40+	Numerous biopharmas commercializing university innovations
Clinical Trial Portfolio (2022)	Several hundred trials across biomedical fields	Similar levels in top U.S. academic institutions	Thousands managed by industry entities

JHU’s research funding places it among top U.S. academic institutions. Its patent activity and licensing generate significant revenue, fueling further R&D. Its collaborations with industry partner companies extend its commercialization reach.

What Are the Strengths of Johns Hopkins in Pharmaceutical Innovation?

• Research Excellence: Consistently ranks among top U.S. institutions for NIH funding and research output (NIH, 2022).
• Strong Collaborations: Extensive partnerships with biotech and pharma companies, including Merck, GSK, and Amgen.
• Institutional Infrastructure: Advanced core facilities and translational research units enable rapid progression from discovery to clinical trials.
• Dedicated Technology Transfer: JHU’s Office of Technology Transfer manages patenting, licensing, and startup formation efficiently.
• Large Clinical Network: Access to Johns Hopkins Medicine’s network of hospitals and clinics facilitates early-stage clinical trials.

What Strategic Initiatives Support JHU’s Competitive Advantage?

• Focus on Oncology and Infectious Diseases: Prioritizes expanding research in cancer, viral diseases, and vaccine development, aligning with global health needs.
• Investment in Digital and Data Science: Integrates AI and machine learning to enhance drug discovery processes.
• Global Health and Equity Programs: Embeds social impact into research, fostering collaborations that address unmet medical needs in underserved populations.
• Industry Collaboration Frameworks: Implements structured partnerships, including licensing agreements and joint ventures, to accelerate development and commercialization.

How Does JHU Position Its Research for Commercial Success?

• Licensing technology to biotech startups and established pharma firms.
• Supporting startup incubators to commercialize promising findings.
• Securing government grants and industry funding, emphasizing translational research.
• Publishing research prominently to attract industry interest and talent.

What Are the Key Challenges for Johns Hopkins in the Pharmaceutical Market?

• Revenue Generation Limitations: As a non-profit academic institution, licensing income is constrained by public and philanthropic funding dynamics.
• Competition for Funding: Maintains a competitive edge amid rising NIH and private sector investments in biomedical research.
• Pathway to Commercialization: Navigating regulatory environments and long development cycles delays market entry.
• Talent Acquisition: Attracting skilled researchers and entrepreneurs in a competitive biotech landscape.
• Scaling Innovations: Transitioning from academic discovery to large-scale manufacturing remains complex and costly.

What Are the Strategic Opportunities for Further Growth?

• Expanding translational research capacity to speed up drug development pipelines.
• Building more industry partnerships for joint research and licensing.
• Developing personalized medicine platforms, leveraging genomic data.
• Targeting emerging disease areas like antibacterial resistance and neurodegeneration.
• Strengthening global health research collaborations.

Key Takeaways

• Johns Hopkins University maintains a robust position within academic biomedical research, with substantial research funding, patent activity, and industry collaborations.
• Its strengths lie in research excellence, translational infrastructure, and strategic partnerships, enabling effective technology commercialization.
• Challenges include revenue limitations, commercialization complexity, and fierce competition for funding and talent.
• Future growth opportunities include expanding translational capacity, adopting digital health technologies, and increasing industry engagement.

FAQs

1. How significant is Johns Hopkins’ contribution to pharmaceutical patents?
   It files over 1,300 patents annually, ranking among top U.S. academic institutions, fueling licensing income and startups.

2. Does Johns Hopkins directly manufacture drugs?
   No; it focuses on discovery, licensing, and supporting startups, with commercialization primarily through licensed technologies.

3. What industries does Johns Hopkins most often collaborate with?
   The university partners with big pharma firms like Merck and GSK, as well as biotechs focused on oncology, infectious disease, and vaccines.

4. Are Johns Hopkins’ innovations protected internationally?
   Yes; patent filings include U.S. and international jurisdictions, enabling global licensing and commercialization.

5. What is Johns Hopkins’ primary focus for future research?
   Emphasis on cancer, infectious diseases, personalized medicine, and digital health innovations to drive translational impact.

---

References

1. National Institutes of Health. (2022). NIH Research Portfolio Online Reporting Tools. https://reporter.nih.gov
2. Johns Hopkins University. (2022). Research and Innovation Data. https://research.jhu.edu
3. Association of American Universities. (2022). The State of University Innovation. https://aau.edu/research
4. Bloomberg Industry Group. (2022). Pharmaceutical R&D Spending. https://bloombergindustry.com